Rapport’s epilepsy drug finds surprising success in bipolar trial

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 20 Oct, 16:27 UTC

Despite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results that could help it tap a billion-dollar-plus market opportunity.

science

Sources

• T2Rapport’s epilepsy drug finds surprising success in bipolar trialBioPharma Dive / Healthcare Dive / MedTech Dive20 Oct, 16:27